A stock that scores a perfect 10 should be on every investor’s list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I’d considering a perfect 10. For this article, I’m using StockRover’s stock screening tool, which screens for such qualities among a very large basket of…

The stock market is on a long-term downtrend as interest rates rise and inflation remains high despite a slight cool-off. Many retirement portfolios that invest in indexes such as S&P500 are down at least 17% year-to-date. That is even more awful when you add inflation to the equation. Of course, no stock is immune to…

My task today is to find seven of the most undervalued long-term stocks to buy now. We need to determine two things before stock selection takes place. First, it’s important to define what is meant by long-term. Secondly, we need to classify what makes a stock undervalued. Every person’s opinion on this subject is different.…

It is hard to justify the moves that Penn National Gaming (NASDAQ:PENN) stock makes. From the depth of the pandemic low to the highs of 2021 it rallied 3,480%. Sadly for those who chased it late, it has given back 63% of it. Today we will try to make sense of this action to find…

Ocugen’s (NASDAQ:OCGN) time in the sun is coming to an end. Last year, the stock shot to prominence due to the Covid-19 crisis. The clinical-stage biopharmaceutical company is partnering with India’s Bharat Biotech to bring Covaxin, a Covid-19 vaccine candidate, to the American markets. Although it has faced delays, the markets were very kind to the…

The omicron variant of Covid-19 has sent several pharmaceutical companies flying higher this past week, such as Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE). Today, shares of Adagio Therapeutics (NASDAQ:ADGI) are soaring higher by 80% after closing the previous trading session 34% higher. The company only has a market capitalization of $5 billion, but it issued a…

As Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron…

News of the omicron Covid-19 variant ravished the markets last week as investors witnessed a drawdown in the S&P 500 and an uptick in the CBOE Volatility Index (VIX). To combat the new variant, Novavax (NASDAQ:NVAX) announced that it is currently developing a vaccine that would target it. In response, shares of NVAX stock have…

Shares of biotech company Ocugen (NASDAQ:OCGN) are sharply lower today on news that the U.S. Food and Drug Administration has halted its investigational new drug application for Covaxin, a vaccine for Covid-19. Source: Shutterstock In a news release, Ocugen said that the FDA still needs to inform it of the reasons why the Covaxin application…

The smartest CEO in America today is a Greek veterinarian named Albert Bourla, CEO of Pfizer (NYSE:PFE). Source: Manuel Esteban / Shutterstock.com Bourla has made Pfizer stock a hot ticket. The stock is up 38% so far in 2021, generating $100 billion in new market capitalization. He has done this with a drug Pfizer didn’t…

While still 50% below its all-time high, Novavax (NASDAQ:NVAX) stock is showing signs of recovery. Source: Ascannio/Shutterstock.com NVAX stock appears to have hit its rock bottom of around $135 per share on Oct. 25. Since then, shares of the biotechnology company have risen to $184 at this writing and are finally trending in the right…

If you happen to be an ardent supporter of Ocugen (NASDAQ:OCGN) stock, you might want to turn away. Source: shutterstock.com/PhotobyTawat While I’m going to assess both sides of the issue, ultimately, OCGN stock depends on a particular brand of sentiment that appears to be fading away. Still, let me acknowledge what a remarkable turnaround this…

Ocugen (NASDAQ:OCGN) has been one of 2021’s most volatile biotech companies. OCGN stock spiked from $2 to above $10 back in February after Ocugen announced that it was partnering with India’s Bharat Biotech on the latter’s Covid-19 vaccine.   Since then, Ocugen has been a roller coaster, dipping to $7 or $8 repeatedly before spiking up…

Things appear to have gone from bad to worse for high-flying pharmaceutical company Moderna (NASDAQ:MRNA) stock, leaving shareholders reeling. Source: Ascannio / Shutterstock.com MRNA stock has cratered, dropping from $350 a share all the way down to $228. The steep fall came after the company reported disappointing quarterly results that shocked Wall Street and revised down…

Novavax (NASDAQ:NVAX) — a biotech company with a Covid-19 vaccine candidate — released its third-quarter earnings on Nov. 4. Now, NVAX stock looks to be too cheap on a forward earnings multiple basis. Source: Ascannio/Shutterstock.com For example, based on five analysts’ average estimates for 2022, one Seeking Alpha survey shows NVAX is very cheap. Trading…

Biopharmaceutical company Ocugen (NASDAQ:OCGN) can’t catch a break. Even after promising news related to Covaxin approval, OCGN stock is down more than 4% on the day as the markets continue to digest its mixed-basket earnings call. Source: shutterstock.com/PhotobyTawat So what do you need to know? It’s an understatement to say that Ocugen has something in…

As recently as late October, it seemed like Novavax (NASDAQ:NVAX) was becoming an “also ran” in the vaccine horse race. For weeks, investors were bailing out of NVAX stock on news of Merck’s (NYSE:MRK) antiviral Covid-19 pill plus reports of NVAX facing production headwinds. Source: Ascannio/Shutterstock.com But now, as positive news is starting to come out? It…

The race to manufacture a Covid-19 vaccine started with Novavax (NASDAQ:NVAX) among the major contenders. However, that seems like eons ago considering the state we find NVAX stock in today. Shares of the biotech have been losing steam for several months now. Although attributable to several factors, this is mostly the company’s own doing. This…